Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.
03.06.2025 17:28:33

bonyf Welcomes Group Pharmaceuticals as Strategic Stakeholder to Drive Growth in India

bonyf NV / Key word(s): Capital Increase/Expansion
bonyf Welcomes Group Pharmaceuticals as Strategic Stakeholder to Drive Growth in India

03-Jun-2025 / 17:28 CET/CEST


bonyf Welcomes Group Pharmaceuticals as Strategic Stakeholder to Drive Growth in India

fncls.ssp?fn=download2_file&code_str=5f0f535be0839ba2a9b5d0a906fccb17

Knokke-Heist (Belgium), 3 June 2025, 6:00 p.m.; bonyf NV (Mnemonic: MLBON), a leader in dental consumer goods, professional dental consumables and dermatological solutions, is proud to announce that Group Pharmaceuticals, a leading Indian oral health company, has become a significant stakeholder in bonyf NV. To date, Group Pharmaceuticals has acquired a total of 13.5% of bonyf’s shares, marking a strong commitment to a long-term strategic partnership. This collaboration represents a major step forward in bonyf’s global expansion and positions the company to accelerate its growth in the Indian market.

Group Pharmaceuticals is a prominent player in India’s oral healthcare sector, with a field force that directly reaches over 100,000 dentists every month. This outstanding market access creates a powerful platform for promoting bonyf’s high-performance oral care products to dental professionals and their patients.

As part of the partnership, Group Pharmaceuticals will also begin local production of selected bonyf-licensed products in India. This move ensures cost-effective manufacturing, regulatory alignment, and streamlined distribution across the region.

Importantly, this alliance reinforces dentist-led product recommendations and builds strong brand trust among patients. In addition, both companies are committed to co-developing new oral care solutions tailored to the needs of the Indian market.

Jean-Pierre Bogaert, CEO of bonyf, stated: “We view this as a very important collaboration. Group Pharmaceuticals’ strong market presence and outstanding network in India will help us realize our international growth ambitions while ensuring that our products reach millions of new patients.”

bonyf sees this strategic investment and collaboration as a key driver for sustainable international growth.

For more information, visit bonyf.com or contact investor@bonyf.com.

 

bonyf’s strengths

  • Products with patented formulations
  • Produced in Switzerland compliant with stringent international quality regulations
  • Proven clinical efficacy
  • Commercial presence in 37 countries
  • Prospects for solid growth and rapid profitability
  • A fast-growing oral and dental care market

 

About bonyf

Incorporated in 1979, bonyf specialises in the development, production and selling of cutting-edge oral & dental care products. bonyf is a forward-thinking company committed to revolutionizing oral care through innovation and research. With a focus on quality and efficacy, bonyf develops cutting-edge products designed to enhance the well-being of individuals worldwide. Through its unwavering commitment to innovation and continuous improvement, bonyf makes a real difference to people suffering from dental and oral conditions. The company has its R&D facilities in Liechtenstein (in the renown dental valley), a production plant in Switzerland and distributes its product range in 37 countries worldwide. Benefiting from seven patent protected formulations and products developed in-house, bonyf expects strong future development, driven by the fast-growing oral and dental care market.

For more information about bonyf and its innovative oral care products, please visit www.bonyf.com.

 

bonyf

Jean-Pierre Bogaert

investor@bonyf.com

 



Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


Language: English
Issuer: bonyf NV
Kalvekeetdijk 179, box 105
8300 Knokke-Heist
Belgium
Phone: +41 79 412 42 79
E-mail: president@bonyf.com
Internet: www.bonyf.com
ISIN: BE6333353298
EQS News ID: 2149994

 
End of Announcement - EQS News Service

2149994  03-Jun-2025 CET/CEST

Analysen zu bonyf

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Die besten Aktien der vergangenen 30 Jahre – Wall Street Live mit Tim Schäfer

Die 10 besten Aktien der letzten 30 Jahre im S&P 500.
Welche Aktien haben in den letzten 30 Jahren im S&P 500 die höchste Rendite erzielt? In diesem spannenden Interview zeigt uns Tim Schäfer ⁨@TimSchaeferMedia⁩ warum es nicht Apple oder Amazon auf Platz 1 geschafft haben, sondern ein Energy-Drink-Hersteller.

Gemeinsam werfen wir einen Blick auf die Top 10 Performer, viele davon überraschend unbekannt.

Highlights der Folge:
🔹 Monster Beverage – Vom Saftladen zum Milliardenunternehmen
🔹 Nvidia – KI-Boom und Chipdesign auf Weltklasse-Niveau
🔹 Amazon – Vom Online-Buchhändler zum globalen Tech-Giganten
🔹 Axon Enterprise – Taser und Bodycams für Polizei und Sicherheit
🔹 Netflix – Streaming-Pionier mit kontinuierlichem Wachstum
🔹 NVR – US-Hausbauer mit extrem teurer Aktie
🔹 Texas Pacific Land – Landbesitzer mit Einnahmen aus Öl und Wasser
🔹 Apple – Innovationsmaschine und Ökosystem mit starker Marge

👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/

Die besten Aktien der vergangenen 30 Jahre – Wall Street Live mit Tim Schäfer

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’395.91 19.21 BJ8SYU
Short 12’647.28 13.69 BANSGU
Short 13’134.20 8.72 BP9SUU
SMI-Kurs: 11’893.82 22.07.2025 17:31:39
Long 11’409.58 19.52 BBWS3U
Long 11’119.74 13.38 BMYSUU
Long 10’683.83 8.99 BUFSYU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

Aktien in diesem Artikel

bonyf 12.90 -7.19% bonyf

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}